OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 27.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 136,516 shares of the company’s stock after acquiring an additional 29,618 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Aura Biosciences were worth $1,122,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in AURA. BNP Paribas Financial Markets purchased a new position in shares of Aura Biosciences in the fourth quarter worth about $50,000. China Universal Asset Management Co. Ltd. purchased a new stake in Aura Biosciences in the fourth quarter valued at approximately $87,000. Harvest Investment Services LLC acquired a new position in Aura Biosciences in the 4th quarter worth approximately $133,000. AlphaQuest LLC purchased a new position in Aura Biosciences during the 4th quarter worth approximately $136,000. Finally, Intech Investment Management LLC acquired a new stake in Aura Biosciences during the 4th quarter valued at approximately $172,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $5.26 on Wednesday. The stock has a market capitalization of $264.18 million, a PE ratio of -3.04 and a beta of 0.43. The company has a fifty day moving average of $6.08 and a two-hundred day moving average of $7.67. Aura Biosciences, Inc. has a fifty-two week low of $4.84 and a fifty-two week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). Research analysts forecast that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on AURA. JMP Securities set a $19.00 price target on shares of Aura Biosciences in a report on Wednesday, March 26th. HC Wainwright set a $25.00 price target on shares of Aura Biosciences in a research report on Tuesday, March 25th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Finally, Citigroup reissued an “outperform” rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aura Biosciences has an average rating of “Buy” and an average target price of $22.75.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Conor Kilroy sold 7,162 shares of Aura Biosciences stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total transaction of $39,319.38. Following the sale, the insider now owns 179,313 shares of the company’s stock, valued at $984,428.37. The trade was a 3.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 14,148 shares of company stock valued at $91,434 over the last quarter. 5.40% of the stock is currently owned by insiders.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.